Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Taiwan Biomateiral Co's Enterprise Value is NT$1,282.2 Mil.
Taiwan Biomateiral Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was NT$45.6 Mil. Therefore, Taiwan Biomateiral Co's EV-to-FCF for today is 28.10.
The historical rank and industry rank for Taiwan Biomateiral Co's EV-to-FCF or its related term are showing as below:
ROCO:6649'
s EV-to-FCF Range Over the Past 10 Years
Min: -214.3 Med: -8.49 Max: 115.21
Current: 29.53
During the past 13 years, the highest EV-to-FCF of Taiwan Biomateiral Co was 115.21. The lowest was -214.30. And the median was -8.49.
ROCO:6649's EV-to-FCF is ranked worse than 61.11% of 414
companies
in the Medical Devices & Instruments industry
Industry Median: 23.21
vs ROCO:6649: 29.53
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Taiwan Biomateiral Co (ROCO:6649) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Taiwan Biomateiral Co's PE Ratio (TTM) for today is calculated as:
Taiwan Biomateiral Co's share price for today is NT$37.75.
Taiwan Biomateiral Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$1.400.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Taiwan Biomateiral Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Taiwan Biomateiral Co EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Taiwan Biomateiral Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Taiwan Biomateiral Co's EV-to-FCF falls into.
Taiwan Biomateiral Co's current Enterprise Value is NT$1,282.2 Mil.
Taiwan Biomateiral Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$45.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Taiwan Biomateiral Co (ROCO:6649) has a EV-to-FCF of 28.10 as of Jul. 21, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Taiwan Biomateiral Co and its competitors. According to the industry distribution chart, Taiwan Biomateiral Co ranks #253 out of 414 companies in the Medical Devices & Instruments industry, placing it in the top 61.1%.
Is Taiwan Biomateiral Co's EV-to-FCF too high?
Taiwan Biomateiral Co's current EV-to-FCF is 28.10. The Medical Devices & Instruments industry median EV-to-FCF is 23.21. Taiwan Biomateiral Co's value of 28.10 is 21.1% above this industry median. Based on the distribution chart, Taiwan Biomateiral Co ranks #253 out of 414 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Taiwan Biomateiral Co has a GF Score™ of 74/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Taiwan Biomateiral Co's EV-to-FCF compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Taiwan Biomateiral Co ranks #253 out of 414 companies for EV-to-FCF. This places Taiwan Biomateiral Co in the lower half of its industry. The industry median EV-to-FCF is 23.21. Taiwan Biomateiral Co's value of 28.10 is 21.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 23.21, based on 414 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Taiwan Biomateiral Co's current EV-to-FCF of 28.10 is 21.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Taiwan Biomateiral Co and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 23.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Taiwan Biomateiral Co's current EV-to-FCF is 28.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Taiwan Biomateiral Co stock overvalued right now?
Based on GuruFocus' analysis, Taiwan Biomateiral Co (ROCO:6649) is currently considered Possible Value Trap. The stock's GF Value™ is NT$77.96, compared to a current price of NT$37.75 — trading 51.6% below its estimated fair value. The current EV-to-FCF is 28.10 and 21.1% above the Medical Devices & Instruments industry median of 23.21. Taiwan Biomateiral Co's overall GF Score™ is 74/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Taiwan Biomateiral Co (ROCO:6649), the current EV-to-FCF is 28.10 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Taiwan Biomateiral Co (ROCO:6649) Overvalued in 2026?
Based on GuruFocus' analysis, Taiwan Biomateiral Co stock appears to be undervalued.
The current stock price of NT$37.75 is trading 51.6% below its estimated GF Value™ of NT$77.96.
GuruFocus considers Taiwan Biomateiral Co to be Possible Value Trap.
Key valuation signals for ROCO:6649:
EV-to-FCF: 28.10
GF Value™: NT$77.96 vs. price of NT$37.75 (51.6% below fair value)
Industry Position: 21.1% above the Medical Devices & Instruments median (#253 of 414)
No single metric tells the full story. See the ROCO:6649 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Taiwan Biomateiral Co Ltd is an applied technology Research and Development Institute in Taiwan. It is engaged in the research and development and sales of implantable medical devices. The company's products include Foamagen, stroke interventional treatment devices.
74GF Score
Get the complete analysis for ROCO:6649
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6649 has been successfully added to your 
